Showing 2 posts of 2 posts found.
The NHS is authorised to use its first two cannabis-based medicines for routine use after NICE saw fit to recommend …
UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS …
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation